These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. Dosh K, Berger PB, Marso S, van Lente F, Brennan DM, Charnigo R, Topol EJ, Steinhubl S. Circ Cardiovasc Interv; 2009 Dec 01; 2(6):503-12. PubMed ID: 20031767 [Abstract] [Full Text] [Related]
7. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E, PEACE Investigators. J Am Coll Cardiol; 2007 Jul 17; 50(3):205-14. PubMed ID: 17631211 [Abstract] [Full Text] [Related]
8. Usefulness of serum N-terminal pro-brain natriuretic peptide to predict in-stent restenosis in patients with preserved left ventricular function and normal troponin I levels. Hong SN, Ahn Y, Yoon NS, Lee KH, Kim YS, Hwang SH, Lee SR, Kim KH, Park HW, Hong YJ, Kim JH, Jeong MH, Cho JG, Park JC, Kang JC. Am J Cardiol; 2007 Apr 15; 99(8):1051-4. PubMed ID: 17437726 [Abstract] [Full Text] [Related]
9. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD, Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Circulation; 2004 Nov 16; 110(20):3206-12. PubMed ID: 15533869 [Abstract] [Full Text] [Related]
10. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. Kragelund C, Grønning B, Køber L, Hildebrandt P, Steffensen R. N Engl J Med; 2005 Feb 17; 352(7):666-75. PubMed ID: 15716560 [Abstract] [Full Text] [Related]
11. Predicting chronic left ventricular dysfunction 90 days after ST-segment elevation myocardial infarction: An Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) Substudy. Ezekowitz JA, Armstrong PW, Granger CB, Theroux P, Stebbins A, Kim RJ, Patel MR. Am Heart J; 2010 Aug 17; 160(2):272-8. PubMed ID: 20691832 [Abstract] [Full Text] [Related]
17. N-terminal pro-B-type natriuretic peptide as a predictor of repeat coronary revascularization. Sir JJ, Chung WY, Hwang SJ, Kang HJ, Cho YS, Koo BK, Chae IH, Choi DJ, Kim HS, Sohn DW, Kim CH, Oh BH, Park YB, Choi YS. Int J Cardiol; 2008 Jun 06; 126(3):322-32. PubMed ID: 17544525 [Abstract] [Full Text] [Related]